| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO and President | Director | Chief Executive Officer
2 companies
Walter V Klemp is CEO and President at MBRX and has filed Form 4s across 2 companies. Walter V Klemp's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $6.0M at current prices.
Historically, Walter V Klemp's trades have earned a below-average insider score of 37/100 across 7 rated trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -56.6%.
The biggest single holding is MBRX (~$6.0M) as CEO and President. Net of sales, the MBRX filings show accumulation of 1,486,867 shares.
Walter V Klemp has 38 Form 4 filings on record from May 2017 to October 2026, across 2 companies: CEO and President at Moleculin Biotech (MBRX), 2017–2026; Director at Autonomix Medical (AMIX), 2024–2026.
The 75 reported transactions were 21 option exercises, 21 tax withholdings, 21 option or other derivative awards and 9 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 6 purchases worth about $581K and 1 sale worth about $170K.
The largest open-market purchase was 675,675 shares of MBRX at an average $0.37 on June 23, 2025, about $250K. Twelve months later MBRX was down 60%.
The only open-market sale was 100,000 shares of MBRX at an average $1.70 on August 16, 2017, about $170K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | MBRX Moleculin Biotech, Inc. | CEO and President | Buy | 533,333 | $0.00 | - | +1,720% | +2.6% | - | |
| Jun 23, 2025 | MBRX Moleculin Biotech, Inc. | CEO and President | Buy | 675,675 | $0.37 | $249,999.75 | +994.6% | +49.0% | -59.8% | |
| Dec 26, 2023 | MBRX Moleculin Biotech, Inc. | CEO and President | Buy | 188,404 | $0.69 | $129,998.76 | +38.3% | -46.0% | -81.8% | |
| Nov 25, 2022 | MBRX Moleculin Biotech, Inc. | CEO and President | Buy | 45,000 | $1.28 | $57,631.50 | +12.3% | -3.9% | -56.5% | |
| Nov 21, 2022 | MBRX Moleculin Biotech, Inc. | CEO and President | Buy | 22,500 | $1.15 | $25,866.00 | +6.6% | +2.4% | -57.9% | |
| Nov 17, 2022 | MBRX Moleculin Biotech, Inc. | CEO and President | Buy | 109,955 | $0.98 | $107,870.64 | +47.3% | +25.0% | -43.3% | |
| Aug 16, 2017 | MBRX Moleculin Biotech, Inc. | Chief Executive Officer | Sell | 100,000 | $1.70 | $170,300.00 | -9.4% | - | - | |
| May 11, 2017 | MBRX Moleculin Biotech, Inc. | Chief Executive Officer | Buy | 12,000 | $0.81 | $9,720.00 | +1.1% | - | - |